Research programme: infectious disease vaccines - Cadila Healthcare

Drug Profile

Research programme: infectious disease vaccines - Cadila Healthcare

Alternative Names: Bivalent Human Papillomavirus (Types 16 L1 & 18 L1); HPV vaccine - Cadila Healthcare

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cadila Healthcare
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diphtheria; Haemophilus infections; Pertussis; Tetanus
  • Research Hepatitis A; Hepatitis B; Hepatitis E; Human papillomavirus infections; Japanese encephalitis; Typhoid

Most Recent Events

  • 29 May 2017 Cadila Healthcare plans a phase I trial for Human papillomavirus infections in India (IM, Injection) (CTRI2017-05-008537)
  • 27 Apr 2016 Cadila Healthcare plans a phase I trial in Diphtheria, Pertussis, Hepatitis B and Haemophilus infections (In volunteers) in India (CTRI2016-04-006886)
  • 20 Mar 2014 Early research prior to March 2014 in Hepatitis A in India and Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top